EI
NPCE icon

EAM Investors’s Neuropace NPCE Stock Holding History

EAM Investors’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630K Sell
39,656
-1,633
-4% -$26.3K 0.06% 260
2026
Q1 		$543K Sell
41,289
-34,511
-46% -$518K 0.06% 260
2025
Q4 		$1.17M Buy
+75,800
New +$1.01M 0.13% 192
2024
Q2 		– Sell
-75,625
Closed -$998K – 316
2024
Q1 		$998K Buy
75,625
+9,484
+14% +$135K 0.16% 170
2023
Q4 		$682K Sell
66,141
-75,475
-53% -$602K 0.12% 199
2023
Q3 		$1.38M Buy
+141,616
New +$829K 0.27% 178

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

EAM Investors's NPCE Position: Q2 2026 in Review

EAM Investors reduced its Neuropace (NPCE) stake by 4% in Q2 2026, selling an estimated $26.3K and leaving 39,656 shares worth $630K. The position accounts for 0.06% of the portfolio, ranked #260.

EAM Investors first reported a position in NPCE in Q3 2023 and has held it in 6 quarters since. The position peaked at $1.38M in Q3 2023. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • EAM Investors held 39,656 shares of Neuropace worth $630K as of Q2 2026.
  • EAM Investors sold 1,633 Neuropace shares in Q2 2026, an estimated $26.3K.
  • Neuropace made up 0.06% of EAM Investors's portfolio in Q2 2026, its #260 holding.
  • EAM Investors first reported a position in Neuropace in Q3 2023 and has held it in 6 quarters since.
  • EAM Investors's Neuropace position peaked at $1.38M in Q3 2023.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on EAM Investors's 13F filing for Q2 2026, filed 13 Aug 2026.